Dicerna Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch DRNA and buy or sell other stocks, ETFs, and their options commission-free!About DRNA
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas.
CEODouglas M. Fambrough, III, PhD
CEODouglas M. Fambrough, III, PhD
Employees—
Employees—
HeadquartersLexington, Massachusetts
HeadquartersLexington, Massachusetts
Founded2006
Founded2006
Employees—
Employees—
DRNA Key Statistics
Market cap2.98B
Market cap2.98B
Price-Earnings ratio-23.44
Price-Earnings ratio-23.44
Dividend yield—
Dividend yield—
Average volume3.20M
Average volume3.20M
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$40.14
52 Week high$40.14
52 Week low$19.06
52 Week low$19.06
Stock Snapshot
The current Dicerna Pharmaceuticals(DRNA) stock price is $38.22, with a market capitalization of 2.98B. The stock trades at a price-to-earnings (P/E) ratio of -23.44.
Dicerna Pharmaceuticals(DRNA) stock opened on 2025-12-24 at —. The price climbed to — and dipped to —.
Dicerna Pharmaceuticals(DRNA) shares are trading with a volume of 0, against a daily average of 3.2M.
In the last year, Dicerna Pharmaceuticals(DRNA) shares hit a 52-week high of $40.14 and a 52-week low of $19.06.
In the last year, Dicerna Pharmaceuticals(DRNA) shares hit a 52-week high of $40.14 and a 52-week low of $19.06.
People also own
Based on the portfolios of people who own DRNA. This list is generated using Robinhood data, and it’s not a recommendation.